Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$289.6 million.

  • Ptc Therapeutics' Cash from Investing Activities fell 57867.14% to -$289.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$628.3 million, marking a year-over-year decrease of 9760.46%. This contributed to the annual value of $44.2 million for FY2024, which is 12499.87% up from last year.
  • Latest data reveals that Ptc Therapeutics reported Cash from Investing Activities of -$289.6 million as of Q3 2025, which was down 57867.14% from -$422.0 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Cash from Investing Activities ranged from a high of $267.7 million in Q4 2024 and a low of -$422.0 million during Q2 2025
  • Moreover, its 5-year median value for Cash from Investing Activities was -$23.8 million (2023), whereas its average is -$27.3 million.
  • Per our database at Business Quant, Ptc Therapeutics' Cash from Investing Activities surged by 38353.92% in 2024 and then crashed by 57867.14% in 2025.
  • Quarter analysis of 5 years shows Ptc Therapeutics' Cash from Investing Activities stood at $68.3 million in 2021, then plummeted by 52.49% to $32.4 million in 2022, then plummeted by 391.06% to -$94.4 million in 2023, then surged by 383.54% to $267.7 million in 2024, then plummeted by 208.18% to -$289.6 million in 2025.
  • Its Cash from Investing Activities stands at -$289.6 million for Q3 2025, versus -$422.0 million for Q2 2025 and -$184.4 million for Q1 2025.